Skip to main content
  • Engineering any genome, at any site, in any way

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech


Caribou Biosciences Appoints Cherry Thomas, MD as Senior Vice President of Clinical Development

May 11, 2020
BERKELEY, Calif.--Caribou Biosciences, Inc., a leading CRISPR genome editing company, today announced the appointment of Cherry Thomas, MD, as Senior Vice President of Clinical Development. In this newly created position, Dr. Thomas will...

Caribou Biosciences and MaxCyte Enter into Clinical and Commercial License Agreement

May 7, 2020
Agreement enables Caribou to utilize MaxCyte’s ExPERT® platform for its CRISPR gene-edited, allogeneic T cell therapy programs BERKELEY, CA, and GAITHERSBURG, MD, May 7, 2020 — Caribou Biosciences, Inc. (“Caribou”), a leading CRISPR genome...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...